Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05003986
Other study ID # RTRX-RE021-201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 12, 2021
Est. completion date June 1, 2025

Study information

Verified date May 2024
Source Travere Therapeutics, Inc.
Contact Travere Call Center
Phone 1-877-659-5518
Email medinfo@travere.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.


Description:

This is a multicenter, open-label, 112-week study of sparsentan in approximately 67 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 3 populations, defined as follows: - Population 1: Subjects with selected proteinuric glomerular diseases associated with Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD) histological patterns - Population 2: Subjects with kidney biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or Alport syndrome (AS) - Population 3: Subjects with kidney biopsy-confirmed IgAN The study will evaluate long-term safety, tolerability, and efficacy with pharmacokinetic (PK) evaluations at Day 1 (Baseline), Day 2 (Visit 4), and Week 12 (Visit 9) in Population 1 and Population 2. In Population 3, PK values will be evaluated at Day 1 (Baseline) and at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96. For Population 1 and Population 2, subjects will be enrolled in 3 cohorts based on age ranges. For Population 3, subjects will be enrolled in one cohort. Study Enrollment: - Population 1: FSGS and/or MCD (30 subjects total) 1. Cohort 1 (6 subjects): ≥8 years to <18 years 2. Cohort 2 (18 subjects): ≥3 years to <8 years 3. Cohort 3 (6 subjects): ≥1 year to <3 years - Population 2: IgAN, IgAV, or AS (27 subjects total) 1. Cohort 1 (9 subjects): ≥8 years to <18 years 2. Cohort 2 (12 subjects): ≥5 years to <8 years 3. Cohort 3 (6 subjects): ≥2 years to <5 years - Population 3: IgAN (10 subjects total) 1. 10 subjects: ≥8 years to <18 years


Recruitment information / eligibility

Status Recruiting
Enrollment 67
Est. completion date June 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria for All Subjects (All Three Populations): A subject must meet all of the following criteria to be eligible for participation in this study: - The subject or parent/legal guardian (as appropriate) is willing and able to provide signed informed consent/assent, and where required, the subject is willing to provide assent before any screening procedures per local requirements. - The subject has an estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 at screening. - The subject has a mean seated blood pressure between the 5th and 95th percentile for sex and height. Inclusion Criteria for Population 1: - The subject is male or female =1 year at screening and <18 years of age at Day 1 (Baseline). - The subject has a UP/C =1.5 g/g (170 mg/mmol) at screening AND one of the following: - Kidney biopsy-proven FSGS or MCD histological patterns and clinical presentation consistent with primary FSGS or MCD and qualifying proteinuria at screening despite history or ongoing treatment with corticosteroids and/or other immunosuppressive disease-modifying agents. - Documentation of a genetic mutation in a podocyte protein associated with FSGS or MCD. Subjects with a documented podocytic mutation do not require kidney biopsy. - Kidney biopsy-proven FSGS histological pattern with medical history and clinical presentation consistent with maladaptive cause of the lesion. Note: The kidney biopsy may have been performed at any time in the past but must include light microscopy and electron microscopy characteristics and/or immunofluorescence findings consistent with FSGS or MCD. Inclusion Criteria for Population 2: - The subject is male or female =2 years at screening and <18 years of age at Day 1 (Baseline). - The subject has UP/C =0.6 g/g (68 mg/mmol) at screening AND one of the following diagnoses: - Kidney biopsy-confirmed IgAN, IgAV, or AS - Diagnosis of AS by genetic testing (pathogenic X-linked Collagen, Type IV, Alpha-5 (COL4A5) mutation OR autosomal-recessive mutations in both alleles of Collagen, Type IV, Alpha-3 (COL4A3) and/or Collagen, Type IV, Alpha-4 (COL4A4) OR autosomal-dominant COL4A3 and/or COL4A4 and digenic mutations [ie, simultaneous mutations in 2 of the COL4A3, COL4A4, and COL4A5 genes]) Inclusion Criteria for Population 3: - The subject is male or female =8 years at screening and <18 years of age at Day 1 (Baseline). - The subject has UP/C =1.0 g/g (113 mg/mmol) at screening AND has kidney biopsy-confirmed IgAN - Subject weighs =40 kg - The subject has been on ACEI and/or ARB therapy for at least 12 weeks prior to screening Exclusion Criteria for All Subjects (All Three Populations): A subject who meets any of the following will be excluded from this study: - The subject weighs <7.3 kg at screening. - The subject has FSGS or MCD histological pattern secondary to viral infections, drug toxicities, or malignancies. - The subject has immunoglobulin A (IgA) glomerular deposits not in the context of primary IgAN or IgAV (ie, secondary to another condition; eg, systemic lupus erythematosus and liver cirrhosis). - The subject has had an acute onset or presentation of glomerular disease or a diagnostic biopsy or a relapse of glomerular disease requiring new or different class of immunosuppressive treatment (including, but not limited to, systemic corticosteroids, calcineurin inhibitors and mycophenolate mofetil, abatacept, cyclophosphamide, rituximab, ofatumumab, and ocrelizumab) within 6 months before screening. - Subjects taking chronic immunosuppressive medications (including systemic steroids) not on a stable dose for =1 month before screening. - The subject requires any of the prohibited concomitant medications as defined in the study protocol. - The subject has undergone any organ transplantation, with the exception of corneal transplants. - The subject has a documented history of congenital or acquired heart failure (modified Ross heart failure classification for children Class II to Class IV) and/or previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and/or peripheral edema. - The subject has hemodynamically significant cardiac valvular disease. - The subject has clinically significant congenital vascular disease. - The subject has jaundice, hepatitis, or known hepatobiliary disease, or alanine aminotransferase and/or aspartate aminotransferase >2 times the upper limit of the normal range at screening. - The subject has a history of malignancy within the past 2 years. - The subject has a screening hematocrit <27% (0.27 L/L) or a hemoglobin value <9 g/dL (90 g/L). - The subject has a screening potassium value >5.5 milliequivalent (mEq)/L (5.5 mmol/L). - The subject has any abnormal clinical laboratory screening values that are considered by the Investigator to be clinically significant. - The subject has a history of allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including sparsentan, or has a hypersensitivity to any of the excipients in the study medication. - The female subject is pregnant, plans to become pregnant during the course of the study, or is breastfeeding. - Female subjects of childbearing potential, beginning at menarche, who do not agree to use 1 highly reliable (ie, can achieve a failure rate of <1% per year) method of contraception from 7 days before the first dose of the study medication until 28 days after the last dose of study medication. Examples of highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with the inhibition of ovulation or an intrauterine device. One additional barrier method must also be used during vaginal sexual activity, such as a diaphragm, diaphragm with spermicide (preferred), or male partner's use of male condom or male condom with spermicide (preferred), from Day 1/Randomization until 28 days after the last dose of study medication. Female subjects of childbearing potential are defined as those who are fertile after menarche, unless permanently sterile; permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. All female subjects of childbearing potential must have a negative serum pregnancy test result at screening (Visit 1) and a negative urine pregnancy test result, with positive results confirmed by serum, at every study visit from Day 1 (Visit 3) and after. Note: Before menarche, pregnancy testing and contraceptive use are not required. However, subjects and their parents/legal guardians must be advised that, immediately upon menarche, subjects will be required to begin pregnancy testing and initiate contraceptive use. This requirement cannot be waived. - The subject has participated in a study of another study medication within 28 days before screening or plans to participate in such a study during the course of this study. - The subject has had prior exposure to sparsentan. - The subject or parent/legal guardian (as appropriate), in the opinion of the Investigator, are unable to adhere to the requirements of the study including but not limited to, a history of noncompliance and/or any other reason that causes the Investigator to believe the subject would not be a good candidate for the study. - For Population 3 - the subject is unable to swallow the study medication tablets whole.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sparsentan
Population 1: 800 mg Sparsentan (oral suspension)
Sparsentan
Population 2: 400 mg Sparsentan (oral suspension)
Sparsentan
Population 3: 400 mg Sparsentan (tablets)

Locations

Country Name City State
Germany Travere Investigational Site Hamburg
Germany Travere Investigational Site Heidelberg
Germany Travere Investigational Site Köln
Italy Travere Investigational Site Bari
Italy Travere Investigational Site Genova
Italy Travere Investigational Site Milano
Italy Travere Investigational Site Padova
Italy Travere Investigational Site Roma
Netherlands Travere Investigational Site Amsterdam
Netherlands Travere Investigational Site Nijmegen
Poland Travere Investigational Site Kraków
Poland Travere Investigational Site Lódz
Poland Travere Investigational Site Warsaw
Spain Travere Investigational Site Barcelona
Spain Travere Investigational Site Madrid
Spain Travere Investigational Site Madrid
Spain Travere Investigational Site Sevilla
Sweden Travere Investigational Site Göteborg
Sweden Travere Investigational Site Stockholm
United Kingdom Travere Investigational Site Bristol
United Kingdom Travere Investigational Site Glasgow
United Kingdom Travere Investigational Site Liverpool
United Kingdom Travere Investigational Site London
United Kingdom Travere Investigational Site Manchester
United States Travere Investigational Site Ann Arbor Michigan
United States Travere Investigational Site Boston Massachusetts
United States Travere Investigational Site Chapel Hill North Carolina
United States Travere Investigational Site Charlotte North Carolina
United States Travere Investigational Site Columbus Ohio
United States Travere Investigational Site Durham North Carolina
United States Travere Investigational Site Hackensack New Jersey
United States Travere Investigational Site Houston Texas
United States Travere Investigational Site Iowa City Iowa
United States Travere Investigational Site Kansas City Missouri
United States Travere Investigational Site Los Angeles California
United States Travere Investigational Site Miami Florida
United States Travere Investigational Site Miami Florida
United States Travere Investigational Site Minneapolis Minnesota
United States Travere Investigational Site Neptune New Jersey
United States Travere Investigational Site New Hyde Park New York
United States Travere Investigational Site New York New York
United States Travere Investigational Site Oklahoma City Oklahoma
United States Travere Investigational Site Philadelphia Pennsylvania
United States Travere Investigational Site Philadelphia Pennsylvania
United States Travere Investigational Site Seattle Washington
United States Travere Investigational Site Wilmington Delaware

Sponsors (1)

Lead Sponsor Collaborator
Travere Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Germany,  Italy,  Netherlands,  Poland,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs) The incidence of TEAEs, SAEs, AEs leading to treatment discontinuation, and AEOIs After the last patient has undergone the week 108 visit (Visit 15).
Primary Urine protein/creatinine ratio (UP/C) at week 108 Change from baseline in UP/C over 108 weeks After the last patient has undergone the Week 108 visit (Visit 15)
Secondary Observed plasma Pharmacokinetic (PK) concentrations Observed plasma PK concentrations at scheduled timepoints and visits At scheduled Day 1, Day 2 and Week 12 visits for Population 1 and 2. At scheduled Day 1 and Week 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 visits for Population 3.
Secondary Steady-state PK parameters area under the plasma concentration-time curve during a dosing interval ([AUCt]) Steady-state PK parameters [AUCt] Week 108
Secondary Steady-state PK parameters [Cmax_ss] Maximum steady-state plasma drug concentration [Cmax_ss] Week 108
Secondary Steady-state PK parameters [Cmin_ss] Minimum steady-state plasma drug concentration [Cmin_ss] Week 108
Secondary Urine albumin/creatinine ratio (UA/C) over 108 weeks Change from baseline in UA/C over 108 weeks Week 108
Secondary Estimated glomerular filtration rate (eGFR) over 108 weeks Change from baseline in eGFR over 108 weeks Week 108
Secondary Proportion of subjects achieving complete remission of proteinuria The proportion of subjects achieving complete remission of proteinuria, defined as UP/C <0.3 g/g over 108 weeks Week 108
Secondary Proportion of subjects with FSGS and/or MCD histological patterns achieving partial remission The proportion of subjects with FSGS and/or MCD histological patterns achieving partial remission defined as UP/C =1.5 g/g and >40% reduction in UP/C over 108 weeks Week 108
Secondary Proportion of subjects who discontinue study medication due to inability to tolerate the oral suspension The proportion of subjects who discontinue study medication due to inability to tolerate the smell, taste, aftertaste, volume of administration, or method of administration of oral suspension in Population 1 and Population 2 Week 108
See also
  Status Clinical Trial Phase
Completed NCT02585804 - Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Phase 4
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Not yet recruiting NCT00956059 - Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Completed NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT01113385 - Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome N/A
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT03703908 - A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome Phase 2
Completed NCT03649152 - Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT00255398 - Kidney Disease Biomarkers
Terminated NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Recruiting NCT02235857 - Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children N/A
Recruiting NCT05942625 - A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects Phase 1
Recruiting NCT02382874 - Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Phase 1
Completed NCT00464321 - Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS Phase 1
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2

External Links